Sugi Predict

Sugi Predict / Compounds / SCHEMBL322156

SCHEMBL322156

SCHEMBL322156

CC(C)(C)OC(=O)NC1CCN(C(=O)C2CCOCC2)C1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.53
▸ HSD11B1 P28845 9/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CTSK P43235 2/20 0.52
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ HPGD P15428 1/20 0.43
▸ BTK Q06187 1/20 0.43
▸ EPHX2 P34913 2/20 0.43
▸ PARP1 P09874 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ EPHX1 P07099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322155 1.00 RECQL (0.53) RECQLHSD11B1CYP2C9CTSKCA1
SCHEMBL15731609 0.91 HSD11B1 (0.58) RECQLHSD11B1CYP2C9CTSKCA1
SCHEMBL20416018 0.86 HSD11B1 (0.54) RECQLHSD11B1CYP2C9CTSKCA1
SCHEMBL19024479 0.86 HSD11B1 (0.54) RECQLHSD11B1CYP2C9CTSKCA1
SCHEMBL13613096 0.85 HSD11B1 (0.53) RECQLHSD11B1CYP2C9CTSKCA1
SCHEMBL4760740 0.83 HSD11B1 (0.54) RECQLHSD11B1CYP2C9CTSKCA1
SCHEMBL22928829 0.82 HPGD (0.54) RECQLHSD11B1CYP2C9CTSKCA1
SCHEMBL1159629 0.82 CA1 (0.67) HSD11B1CYP2C9CTSKCA1CA2
SCHEMBL1226780 0.82 RECQL (0.63) RECQLHSD11B1CYP2C9CTSKCA1
SCHEMBL1159627 0.82 CA1 (0.67) HSD11B1CYP2C9CTSKCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059181-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2025-02-20 — — US disclosed
US-20220267318-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2022-08-25 — — US disclosed
US-20200392132-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2020-12-17 — — US disclosed
US-20190218217-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors NOVARTIS AG (CH) 2019-07-18 — — US disclosed
US-20190040061-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2019-02-07 — — US disclosed
US-20180265509-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2018-09-20 — — US disclosed
US-9949979-B2 Use of inhibitors of the activity or function of PI3K NOVARTIS AG (CH) 2018-04-24 — — US disclosed
US-20170267678-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2017-09-21 — — US disclosed
US-20170022199-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2017-01-26 — — US disclosed
US-9499536-B2 Tetrahydro-pyrido-pyrimidine derivatives NOVARTIS AG (CH) 2016-11-22 — — US disclosed
US-20150342951-A1 Use of Inhibitors of the Activity or Function of PI3K NOVARTIS AG (CH) 2015-12-03 — — US disclosed
EP-2790705-A1 USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K Novartis AG (CH) 2014-10-22 — — EP disclosed
EP-2590974-B1 TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2014-05-21 — — EP disclosed
US-20140128370-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2014-05-08 — — US disclosed
US-8653092-B2 Tetrahydro-pyrido-pyrimidine derivatives NOVARTIS AG (CH) 2014-02-18 — — US disclosed
WO-2013088404-A1 Use of inhibitors of the activity or function of PI3K NOVARTIS AG (CH) 2013-06-20 — — WO disclosed
EP-2590974-A1 TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES Novartis AG (CH) 2013-05-15 — — EP disclosed
US-20120065183-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2012-03-15 — — US disclosed
WO-2012004299-A1 TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190040061-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS RECQL 134/4885HSD11B1 937/4885CYP2C9 794/4885
US-20220267318-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS RECQL 134/4885HSD11B1 937/4885CYP2C9 794/4885
US-20170267678-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS RECQL 134/4885HSD11B1 937/4885CYP2C9 794/4885
US-20250059181-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS RECQL 134/4885HSD11B1 937/4885CYP2C9 794/4885
US-20120065183-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS RECQL 134/4885HSD11B1 937/4885CYP2C9 794/4885
US-20200392132-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS RECQL 134/4885HSD11B1 937/4885CYP2C9 794/4885
US-20140128370-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS RECQL 134/4885HSD11B1 937/4885CYP2C9 794/4885
US-20190218217-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors PIK3CA, PIK3CD, PIK3CB RECQL 158/4885HSD11B1 881/4885CYP2C9 1480/4885
US-20170022199-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS RECQL 134/4885HSD11B1 937/4885CYP2C9 794/4885
US-20150342951-A1 Use of Inhibitors of the Activity or Function of PI3K TLR9, PIK3CD, PIK3R5 RECQL 2791/4885HSD11B1 3518/4885CYP2C9 4617/4885
US-20180265509-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS RECQL 134/4885HSD11B1 937/4885CYP2C9 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.